Patent ID: 8999390
Filing Date: 2015-04-07
Classification: A61K,A61P

Abstract:
1. A sustained release pharmaceutical composition in the form of microparticles comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and a biocompatible polymer matrix which is a polymer blend comprising a first linear polylactide-co-glycolide polymer (PLGA) having a lactide:glycolide ratio of 85:15, a second linear PLGA having a lactide:glycolide ratio of 75:25 and a third linear PLGA having a lactide:glycolide ratio of 65:35, with each PLGA having an inherent viscosity below 0.9 dl/g in CHCl 3 , wherein octreotide is released from the composition at a rate which maintains plasma levels of octreotide within the therapeutic range for a period of between three and six months.